
|Videos|July 6, 2017
Dr. Modest on Study of Surgical Intervention in CRC
Author(s)Dominik P. Modest, MD
Dominik P. Modest, MD, University of Munich, discusses an evaluation of resection in patients with metastatic colorectal cancer.
Advertisement
Dominik P. Modest, MD, University of Munich, discusses an evaluation of resection in patients with metastatic colorectal cancer (mCRC).
In a central evaluation for surgical treatment options in the FIRE-3 study results, a panel of 8 surgeons and 3 medical oncologists served as reviewers of 448 patients, defining resectability as at least 50% of the reviewers recommending surgical intervention.
Findings showed that roughly 20% of the population would have been a candidate for surgical intervention and at best response, it was a little more than 50%, says Modest.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
3
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
4
FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care
5




































